A new FDA strategy aims to get medicines to the market faster
Business Report
Last updated: June 30, 2026
The FDA has launched a new strategy to expedite the market entry of medicines by focusing on domestic drug manufacturing. This pilot program involves Eli Lilly and Regeneron to test modernized oversight of pharmaceutical production site construction and readiness. The core aim is to engage with companies earlier in the development lifecycle.
- The initiative intends to streamline the drug approval process by improving the efficiency of pharmaceutical manufacturing facility oversight. By collaborating with selected companies like Eli Lilly and Regeneron, the FDA seeks to identify and address potential issues during the construction and operational readiness phases of these facilities. This proactive approach is expected to reduce delays in bringing essential medicines to patients. The program represents a shift in the FDA's regulatory model, moving towards a more collaborative and forward-looking engagement with the pharmaceutical industry. This aims to foster innovation and ensure a robust domestic supply chain for critical medications.
